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Introduction
In the hierarchy of epidemiological evidence on causes 
of cancer, longitudinal studies (either nested case–control 
or case–cohort studies) are second only to randomized 
trial evidence [1, 2]. The Finnish Maternity Cohort (FMC) 
was established in 1983 to provide a resource for such 
studies. All women in Finland are at their 12th week of 
pregnancy offered screening for congenital infections (hepa-
titis B, HIV, and syphilis). The residual serum samples 
are stored in the FMC [3]. There is a separate legal basis 
for the collection and scientific use of FMC (The law of 
the National Institute for Health and Welfare 668/2008). 
Since 2001, a nationwide informed consent system based 
on the opt- out principle with negligible drop out has 
been in operation.
An example of pioneering cancer research based on 
the FMC are longitudinal studies documenting that 
exposure to human papillomavirus (HPV) types 16 and 
18 causes an excess risk for later development of both 
cervical, other anogenital and oropharyngeal cancers 
[4–6]. FMC’s serial samples have been useful for dis-
entangling the temporal order of events in carcinogenesis, 
for example, antagonistic interaction of different HPV 
types [7], and disclosing smoking as an independent 
risk factor of cervical cancer [8]. The prediagnostic serial 
samples also enable studies on the sensitivity and speci-
ficity of biomarkers for future cancer diagnosis and 
screening [9]. High- quality data on the gestational date 
of the sample collection enable studies on hormones 
and cancer [10]. The FMC is positioned as an inter-
national Open Access resource. Linkage of personal 
identifiers with the nationwide, population- based Finnish 
Cancer Registry and other population- based health and 
trial registries establishes a unique study base for lon-
gitudinal studies [11].
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Abstract
Population- based Finnish Maternity Cohort (FMC) comprises 2M first trimester 
sera collected from 1M women during 33 years. Informed consent is by the 
opt- out principle, and linkages with cancer and population registries provide a 
base for over time and over generation studies. Follow- up for 17M person- years 
by the end of 2014 can identify 39,700 cases of invasive cancer and 18,900 cases 
of premalignant breast and cervix lesions, and basal cell carcinoma diagnosed 
after serum sampling. For women with multiple pregnancies, serial samples 
taken before cancer diagnosis are available. Offspring of the women have 
developed more than 4000 cancers. For 100,000 individuals, samples taken dur-
ing the pregnancies of both their mothers and grandmothers enable familial 
cancer studies. FMC continues to collect samples, and surveillance of exposures 
or interventions like vaccination programs is feasible. In summary, the FMC is 
a unique, accessible biobank for epidemiological, biomarker, and surveillance 
studies on cancer.
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Table 1. Estimated1 numbers of incident invasive cancer cases in the Finnish Maternity Cohort 1983–2014.
Primary site ICD- 10 code
After first sample 
(N = 953,000)
After second sample 
(N = 604,000)
After third sample 
(N = 240,000)
All sites C00–96, D32–33, D42–43, 
D45–47, D76
39,700 19,900 6800
Mouth, pharynx C00–14 490 220 85
Lip C00 10 5 1
Tongue C02 110 50 5
Mouth, other C03–06 110 50 15
Salivary glands C07–08 110 50 20
Pharynx C01, C09–14 130 55 20
Digestive organs C15–26 3900 1900 700
Esophagus C15 65 30 10
Stomach C16 550 280 95
Small intestine C17 110 55 20
Colon C18 1400 700 250
Rectum, rectosigmoid, 
anus
C19–20 790 380 130
Liver C22 135 50 20
Gallbladder, bile ducts C23–24 140 60 20
Pancreas C25 530 230 85
Other digestive organs C26 30 10 0
Respiratory organs C30–39 1050 420 130
Nose, sinuses C30–31 35 15 5
Larynx, epiglottis C32 15 5 2
Lung, trachea C33–34 980 350 110
Mediastinum, pleura C38 10 8 4
Bone C40–41 90 40 10
Melanoma of the skin C43 2200 1200 430
Skin, nonmelanoma C44 400 180 60
Mesothelioma C45 20 9 3
Autonomic nervous system C47 10 4 0
Soft tissues C48–49 280 140 60
Breast C50 18,400 9200 3000
Female genital organs C51–58 3800 1700 550
Cervix uteri C53 1130 630 260
Corpus uteri C54 1100 400 130
Uterus, other C55, C58 20 5 1
Ovary C56 1100 500 150
Other female genital C51–52, C57 280 110 25
Placenta 15 4 2
Urinary organs C64–68 900 400 160
Kidney C64 620 290 120
Bladder and urinary tract C65–68 270 110 40
Eye C69 70 30 10
Brain, central nervous 
system
C70–72, D32–33, D42–43 2500 1400 500
Thyroid gland C73 2300 1300 520
Other endocrine glands C74–75 50 20 5
Ill defined or unknown C76, C80 300 130 40
Lymphoid and hematopoi-
etic tissue
C81–96, D45–47, D76 2600 1300 430
Hodgkin lymphoma C81 350 180 55
Non- Hodgkin lymphoma C82–86, C96, D76 1200 600 200
Myeloma C90 220 100 25
Leukemia C91–95 600 300 90
196% of the Finnish pregnant women between 1983 and 2016 have consented to participate in the FMC. As the women can withdraw consent at 
will the numbers should be considered as estimates.
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Material and Methods
At the end of 2016 the FMC comprised 2.0 million serum 
samples from about 1 million women. As the congenital 
screening is repeated on each pregnancy, serial samples 
are available for about 50% of the women. Moreover, 
there are approximately 100,000 pairs of mothers and 
daughters, who both have donated sera to the FMC for 
scientific research.
We estimated the numbers of incident cancer cases in 
the FMC (Table 1). Cancer incidence in the FMC is similar 
to that in the general female population for all cancer 
types [11], with the exception of endometrial cancer which 
is decreased (43%) due to protection from pregnancy. 
Thus, it was possible to estimate the number of cancer 
cases by multiplying the person- years generated by women 
in FMC by the end of year 2014 with cancer incidence 
rate in the Finnish female population in each 5- year age 
category (www.cancerregistry.fi).
Results
There are approximately 40,000 prospectively occurring 
cases of cancer within 17.2 million person- years of follow-
 up up to 2014. During the first 5 years after pregnancy, 
the number of new cancer cases is moderate but increases 
when the women become older. Breast cancer comprised 
almost half of all incident invasive cancer cases identified 
(18,400 cases, Table 1).
The next 10 most common cancer types were as fol-
lows: thyroid cancer (2300 cases), melanoma (2200 cases), 
colorectal cancers (2190 cases), lymphomas (1550 cases), 
cervical cancer (1130 cases), endometrial cancer (1100 
Table 2. Estimated1 numbers of incident invasive cancer cases in the offspring of the Finnish Maternity Cohort participants (FMC) 1983–2014.
Cancer type ICD10
Boys Girls All
0–4 5–9 1 ± 14 0–14 0–4 5–9 10–14 0–14 0–4 5–9 10–14 0–14
All sites C00–96, 
D32–33, 
D42–43, 
D45–47, D76
1180 535 445 2160 1020 420 410 1850 2200 955 855 4010
Mouth, pharynx C00–14 <5 <5 10 10 0 <5 5 10 <5 5 15 20
Digestive organs C15–26 20 10 25 60 15 10 45 70 35 25 70 130
Respiratory 
organs
C30–39 10 <5 5 15 10 5 0 15 15 10 5 30
Female genital 
organs
C51–58 10 5 20 35 10 5 20 35
Male genital 
organs
C60–63 30 5 5 40 30 5 5 40
Urinary organs C64–68 110 20 5 135 105 20 5 130 220 40 10 270
Melanoma of 
the skin
C43 5 5 15 20 0 5 10 15 5 10 20 35
Skin, 
nonmelanoma
C44 0 5 5 10 5 0 5 5 5 5 5 15
Eye C69 55 5 5 65 45 5 5 50 105 5 5 115
Thyroid gland C73 5 5 5 15 0 5 15 20 5 10 20 35
Other endocrine 
glands
C74–75 90 10 10 110 90 5 5 100 180 15 15 210
Bone C40–41 5 15 25 45 15 10 25 50 15 20 55 90
Soft tissues C48–49 40 20 15 75 45 20 10 75 90 35 30 155
Ill defined or 
unknown
C76, C80 5 5 5 15 5 5 5 15 10 10 5 25
Autonomic 
nervous system
C47 40 5 5 50 40 5 5 50 80 5 5 90
Brain, CNS C70–72, 
D32–33, 42–43
265 185 140 590 195 145 115 455 460 330 260 1050
Lymphoid, 
hematopoetic 
tissue
C81–96, 
D45–47, D76
500 235 175 910 445 175 155 770 940 410 325 1675
196% of all Finnish pregnant women between 1983 and 2014 have consented to participate in the FMC. As the women can later withdraw consent 
at will the numbers should be considered as estimates.
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cases), ovarian cancer (1100 cases), lung cancer (980 cases), 
kidney cancer (620 cases), and leukemia (600 cases). 
Noninvasive cancers include 10,000 cases of in situ cervi-
cal cancer, 7400 cases of basal cell carcinomas, and 1500 
cases of in situ breast carcinomas.
The number of childhood cancer cases in the offspring 
of the FMC donors (4000 cases) is sizeable (Table 2). 
Especially, the numbers of childhood leukemias and lym-
phomas (altogether more than 1600 cases) are high (Table 2).
Discussion
Cancer incidence in the FMC is similar to that in the 
general female population for all cancer types [11], with 
the exception of endometrial cancer which is decreased 
(43%) due to protection from pregnancy. With only 20 
women opting out in 2017, the population- based nature 
of FMC remains virtually intact.
In addition to longitudinal studies on cancer etiology 
and screening studies, the resource is also potentially use-
ful for studies on genetic cancer risk. However, the first 
trimester serum samples contain measurable amounts of 
fetal DNA, which needs to be controlled for in genetic 
studies [12]. Because the FMC is nationwide and contains 
samples from 94% of all Finnish pregnant women [11], 
very large- scale over- generation studies can be designed 
by linking the identities of the mothers to their offspring 
and/or relatives [13]. Due to the long history of the FMC, 
prospects for studying congenital causes of cancer in the 
offspring of the women in FMC are also good.
Ongoing FMC projects include studies of the possible 
role of the same microbiome, that is, similar serological 
signature for mothers and daughters with the same cancer 
for the same types of Chlamydia trachomatis [14], HPV 
[7], Helicobacter pylori, or Streptococcus galolyticus in familial 
cervical, colorectal, and stomach cancers, respectively.
The FMC sample collection can also support clinical 
trials and surveillance purposes, including cancer control. 
For example, we are currently comparing the long- term 
stability of antibody responses induced by either quad-
rivalent or bivalent vaccines against HPV among women 
who participated as adolescents in large randomized albeit 
population- based trials of these vaccines [15]. By linking 
the clinical trial files to the FMC files, it has been pos-
sible to identify serum samples collected up to 14 years 
postvaccination. Evaluation of vaccine- induced antibody 
response in yet- to- be- identified breakthrough cases makes 
search for correlates of protective immunity feasible.
This cohort profile describes the basic characteristics 
of the FMC and provides some examples of its potential 
use. The FMC is also a role model in strict safe guard-
ing of integrity and compliance with data protection 
laws. While linkages of course need to be performed 
with identifiable data, once the samples are retrieved 
they are pseudonymized and it is not possible to link 
the research data to an identifiable individual. To pro-
mote the use of the FMC as an international resource 
for epidemiological cancer research, an international 
nonprofit company (ESIS EEIG) specializing in assisting 
international researchers with the data and samples they 
need has been founded and is available to facilitate the 
formal and logistic process to obtain access to the sam-
ples and data that international cancer research may 
need (www.esis.fi).
Acknowledgments
We thank P. Koskela, who originally established the FMC 
Biobank.
Conflicts of Interest
None declared.
References
 1. Hill, A. B. 1965. The environment and disease: 
association or causation. Proc. R. Soc. Med. 58:295–300.
 2. Doll, R., and R. Peto. 1981. Causes of cancer. J. Natl. 
Cancer Inst. 166:1191–1308.
 3. Koskela, P., T. Anttila, T. Bjorge, A. Brunsvig, J. 
Dillner, M. Hakama, et al. 2000. Chlamydia trachomatis 
infection is a risk factor for cervical cancer. Int. J. 
Cancer 85:35–39.
 4. Dillner, J., M. Lehtinen, T. Bjorge, T. Luostarinen, L. 
Youngman, E. Jellum, et al. 1997. A prospective 
seroepidemiological study of human papillomavirus 
infection as arisk factor for invasive cervical cancer. J. 
Natl. Cancer Inst. 89:1293–1299.
 5. Bjorge, T., J. Dillner, T. Anttila, V. Abeler, A. Engeland, 
T. Hakulinen, et al. 1997. A prospective 
seroepidemiological study of human papillomavirus and 
non- cervical anogenital cancers. BMJ 315:646–649.
 6. Mork, J., A.-K. Lie, E. Glattre, S. Clark, G. Hallmans, 
E. Jellum, et al. 2001. A prospective study on human 
papillomavirus as a risk factor for head and neck 
cancer. N. Engl. J. Med. 344:1125–1231.
 7. Luostarinen, T., P. Namujju, M. Merikukka, H. M. 
Surcel, T. Hakulinen, J. Dillner, et al. 2013. Order of 
prevalent/incident sexually transmitted infections and the 
risk of CIN grade 3. Int. J. Cancer 133:1756–1760.
 8. Kapeu, A., L. Youngman, E. Jellum, J. Dillner, M. 
Hakama, P. Koskela, et al. 2009. Smoking is an 
independent risk factor of cervical cancer. Am. J. 
Epidemiol. 169:480–488.
 9. Lehtinen, M., P. Koskela, H. Ögmundsdottir, A. Bloigu, 
J. Dillner, M. Gudnadottir, et al. 2003. Maternal 
3064 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
M. Lehtinen et al.Cancer Cases in Maternity Cohort 
herpesvirus infections and risk of acute lymphoblastic 
leukaemia in the offspring. Am. J. Epidemiol. 
158:207–213.
10. Fortner, R., H. Schock, R. Kaaks, M. Lehtinen, E. 
Pukkala, H. Å. Lakso, et al. 2017. Human chronionic 
gonadotropin and maternal breast cancer: a nested 
case- control study in the Finnish Maternity Cohort. 
Can. Res. 77:134–141.
11. Pukkala, E., A. Anderssen, G. Berglund, R. Gislefoss, V. 
Gudnason, G. Hallmans, et al. 2007. Nordic biological 
specimen banks as basis for studies of cancer causes 
and control – more than 2 million sample donors, 
25 million person years and 100,000 prospective cancers. 
Acta Oncol. 46:286–307.
12. Sjöholm, M. I., G. Hoffman, S. Lindgren, J. Dillner, 
and J. Carlson. 2005. Comparison of archival plasma 
and formalin- fixed paraffin- embedded tissue for 
genotyping in hepatocellular carcinoma. Cancer 
Epidemiol. Biomarkers Prev. 14:251–255.
13. Lehtinen, M., M. Pawlita, K. Zumbach, M. Hakama, E. 
Jellum, P. Koskela, et al. 2003. Evaluation of antibody 
response to human pillomavirus early proteins in 
women who developed cervical cancer 1- 20 years later. 
Am. J. Obstet. Gynecol. 88:49–55.
14. Anttila, T., P. Saikku, P. Koskela, A. Bloigu, J. Dillner, 
I. Ikäheimo, et al. 2001. Serotypes of Chlamydia 
trachomatis and risk for cervical squamous cell 
carcinoma. JAMA 285:46–51.
15. Lehtinen, M., and J. Dillner. 2013. Clinical HPV 
vaccination trials and beyond. Nat. Rev. Clin. Oncol. 
10:400–410.
